Are you a pharmaceutical or medical device company ready to seize the spotlight in the world of urology and oncology? Act swiftly and secure your 2024 AUANewsWorthy Webinar - a premium platform to host your non-CME education and engage with urologists, oncologists, residents, fellows, and advanced practice providers (APPs). With only one opportunity available each month, this is your chance to showcase, educate, and connect with your target audience.
Don't miss your chance to be part of this exclusive series. These webinars are scheduled for the 3rd Thursday of each month at 3pm Eastern.
Reserved
Reserved
Reserved
Available
Reserved
Reserved
Reserved
Available
Reserved
Available
Reserved
Available
An exclusive webinar page on
AUANews.net dedicated to your event to include:
Up to three pre-approved supplemental materials for maximum engagement
Event Description
Speaker Bio(s) and Headshot(s)
Personalized RSVP for your webinar that will send interested attendees a calendar invite
Promotional emails sent twice a month to AUA members. Every email will include:
A leaderboard ad (featuring the sponsoring company for that month)
A webinar spotlight section to include the event date, title, description, speaker bio(s) and headshot(s) for the webinar occurring that month
A full schedule of upcoming webinars as well as links to past webinars available on-demand
Seamless logistical support and cutting-edge software platform
A direct link to the webinar and on-demand viewing page for you to promote to your clients
Continuous visibility through upcoming and past webinar listings, reinforcing your presence
Strategic social media posts to amplify your industry impact
In order to market your program effectively we’ll need the following details at least one month prior to your program:
High-resolution logo for impactful branding
An attention-grabbing 650x80 banner ad for impactful email campaigns
An engaging Program Title that captivates interest
A concise Program Description (500 characters or less) to intrigue your audience
Speaker(s) information, including compelling bios (500 characters or less) and professional headshots
Speaker names are utilized in all marketing emails throughout the year
Speaker name(s), headshot(s) and bio(s) are utilized in the marketing emails during the month of your webinar and on your webinar page on the AUANews site
Tailor your engagement experience to your preference:
Presentation Options:
Chat Options:
Live Q&A Options:
With limited space and exceptional competitiveness, seize the chance to secure a spot on your customer's calendar in 2024.
The AUA Clinical Guidelines continue to be the number one benefit of AUA members. Used by the global urology community, the AUA Clinical Guidelines are an integral element of clinical urology.
*Licensing the AUA Clinical Guidelines is available.
Use of one AUA clinical guideline in one asset for 12 months - $10,000 per guideline/asset
Use of one AUA clinical guideline in unlimited assets for 12 months - $50,000 per guideline
Use of all AUA clinical guidelines in unlimited assets for 12 months - $100,000
*AUA will need to approve the content of each asset, including any edits to an existing approved asset.
As of January 2024
Benign Prostatic Hyperplasia (2021, Amended 2023)
Bladder Cancer (2):
Muscle Invasive (2017, Amended 2020; AUA/ASCO/ASTRO/SUO) *Under Revision
Non-Muscle Invasive (2016, Amended 2020, 2024; AUA/SUO)
Cryptorchidism (2014, Validity Confirmed 2018) *Under Review
Incontinence (3):
Incontinence after Prostate Treatment (2019; AUA/SUFU) *Under Revision
Non-Neurogenic Overactive Bladder in Adults (2012, Amended 2014, 2019; AUA/SUFU) *New Guideline Due 2024
Stress Urinary Incontinence (2017, Amended 2023; AUA/SUFU)
Interstitial Cystitis/Bladder Pain Syndrome (2011, Amended 2014, 2022)
Male Infertility (2020; AUA/ASRM) *Under Revision
Male Sexual Dysfunction (5):
Disorders of Ejaculation (2020; AUA/SMSNA)
Erectile Dysfunction (2018)
Peyronie’s Disease (2015)
Priapism (2022; AUA/SMSNA)
Testosterone Deficiency (2018) *Under Review
Microhematuria (2020; AUA/SUFU) *Under Review
Neurogenic Lower Urinary Tract Dysfunction (2021; AUA/SUFU)
Prostate Cancer (5):
Adjuvant and Salvage Radiotherapy after Prostatectomy (2013, Amended 2018, 2019; AUA/ASTRO) *New Guideline due 2024
Advanced Prostate Cancer (2020, Amended 2023; AUA/SUO)
Clinically Localized (2022; AUA/ASTRO)
Early Detection (2023; AUA/SUO)
Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO and AUA Evidence-Based Guideline (2018)
Recurrent Urinary Tract Infections in Women (2019, Validity Confirmed 2022; AUA/CUA/SUFU)
Renal Mass and Localized Renal Cancer (2017; Amended 2021)
Stone Disease (2): *New Guideline Due 2025/2026
Testicular Cancer (2019, Amended 2023)
Upper Tract Urothelial Carcinoma (2023; AUA/SUO)
Urethral Strictures (2016, Amended 2023)
Urotrauma (2014; Amended 2017, 2020)
Vasectomy (2012; Validity Confirmed 2015) *New Guideline Due 2025
Vesicoureteral Reflux (2010, Amended 2017, Validity Confirmed 2022)
Salvage Therapy (Due 2024; AUA/ASTRO/SUO
Overactive Bladder (Due 2024; AUA/SUFU)
Genitourinary Syndrome of Menopause (Due 2024; AUA/AUGS/SUFU)
Chronic Pelvic Pain in Men (Due 2024)
Stone Disease, Medical and Surgical (Due 2025/2026)
Vasectomy (Due 2025)
Our trusted journals, news magazine, website and newsletters keep our members current on the developments in urology, so they can offer the best care possible to their patients. Print and digital ads provide your company with branding, traffic building and lead generation to reach your target audience.
Opportunities with Ascend Media include (but are not limited to): AUA Daily News ePreviews, virtual platform login emails, AUA Daily eNews, doctors bag inserts, attendee welcome guides, AUA Daily News eHighlights and much more.
View Media KitFor questions or inquiries, please contact Bridget, Cathleen or Maureen.
Opportunities with The Walchli Tauber Group include (but are not limited to),
AUANews print ads,
NetNews email ads, Policy & Advocacy Brief email ads,
AUAnet.org ads, AUA2023 website ads and retargeting campaigns.
For questions or inquiries please contact:
